Rege Nephro Co., Ltd., a Kyoto University spin-off biotech startup, utilizes iPSC technology. Our lead products include RN-014, a small-molecule for autosomal dominant polycystic kidney disease (ADPKD), and RN-032, an allogeneic cell therapy for chronic kidney disease using iPSC-derived nephron progenitor cells.
This is some text inside of a div block.
